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ABSTRACT
Human vaults are the largest cytoplasmic ribonu-
cleoprotein and are overexpressed in cancer cells.
Vaults reportedly function in the extrusion of xenobi-
otics from the nuclei of resistant cells, but the
interactions of xenobiotics with the vault-associated
proteinsornon-codingRNAshaveneverbeendirectly
observed. In the present study, we show that vault
RNAs (vRNAs), specifically the hvg-1 and hvg-2
RNAs, bind to a chemotherapeutic compound, mitox-
antrone.Usinganin-lineprobingassay(spontaneous
transesterification of RNA linkages), we have identi-
fied the mitoxantrone binding region within the
vRNAs. In addition, we analyzed the interactions
between vRNAs and mitoxantrone in the cellular
milieu, using an in vitro translation inhibition assay.
Taken together, our results clearly suggest that
vRNAs have the ability to bind certain chemothera-
peutic compounds and these interactions may play
an important role in vault function, by participating
in the export of toxic compounds.
INTRODUCTION
Vaults are barrel-shaped particles with a mass of 13 MDa and
represent the largest ribonucleoprotein complex of eukaryotic
cells identiﬁed thus far. They exist in diverse eukaryotic
species, including mammals, avians and amphibians, and their
considerable abundance and striking evolutionary conserva-
tion argue for an important cellular function (1). Vault parti-
cles appear to reside in both the cytoplasm and the nucleus
(2,3) and have been implicated in intracellular (4) and
nucleocytoplasmic transport (2,3). Several lines of evidence
suggest that vaults may play an important role in intracellular
detoxiﬁcation processes, and thus function in the multidrug
resistance (MDR) of cancer cells (5,6).
The human vault constitutes of three proteins [major vault
protein (MVP), telomerase-associated protein 1 (TEP1) and
vault poly(ADP–ribose)polymerase (VPARP)] and three non-
coding RNAs (hvg-1, hvg-2 and hvg-3). These RNAs repres-
ent <5% of the mass of the vault complex and share  84%
sequence identity, but their lengths differ. Human hvg-1 RNA
is 98 bases in length, and the other two RNAs are 88 bases
long. In humans, the genes for these RNAs are located on
chromosome 5.
A previous study on several non-P-glycoprotein MDR cell
lines with increased MVP levels demonstrated that the vault
RNAs (vRNAs) and MVP are coordinately regulated, and
suggested that the entire vault particle is up-regulated in
MDR and that a threshold level of vaults is required to impart
MDR (7). In a clinical scenario, the elevated expression of
MVP was observed in cell lines resistant to various classes of
chemotherapeutic compounds, including doxorubicin and
mitoxantrone (8). Support for the role of vaults inthe extrusion
of anthracyclines from the nuclei of resistance cells was
reported by Ohno et al. (9). However, to date, no vault
components that participate or interact directly with the
chemotherapeutic compound(s) have been identiﬁed, and
thus the function of vaults has remained enigmatic.
RNA molecules are involved in many important metabolic
processes, including peptide bond formation and replication
(10,11). In recentyears, non-codingRNAs have been shown to
participate in complex communication pathways in gene regu-
lation and cell development (12,13). The vRNAs isolated
previously from different species were predicted to fold in
a similar fashion, despite their differences in length, indicating
that the association of vRNAs with vaults is not fortuitous
*To whom correspondence should be addressed. Tel: +81 298 61 6085; Fax: +81 298 61 6095; Email: pkr-kumar@aist.go.jp
  The Author 2005. Published by Oxford University Press. All rights reserved.
The online version of this article has been published under an open access model. Users are entitled to use, reproduce, disseminate, or display the open access
version of this article for non-commercial purposes provided that: the original authorship is properly and fully attributed; the Journal and Oxford University Press
areattributedastheoriginalplaceofpublicationwiththecorrectcitationdetailsgiven;ifanarticleissubsequentlyreproducedordisseminatednotinitsentiretybut
only in part or as a derivative work this must be clearly indicated. For commercial re-use, please contact journals.permissions@oupjournals.org
4874–4881 Nucleic Acids Research, 2005, Vol. 33, No. 15
doi:10.1093/nar/gki809(14). The vRNA ends (50 and 30) form stem-like structures,
but the internal sequences of these RNAs appear to fold
differently. These predictions suggest that vRNAs have a
fundamental role in the function of the vault particle, possibly
through RNA–ligand, RNA–RNA or RNA–protein interac-
tions. Here, we provide the ﬁrst evidence that vault-
associated RNAs interact directly with chemotherapeutic
compounds, suggesting that vRNAs play important roles in
vault function in the cells.
MATERIALS AND METHODS
RNA synthesis
The 98merhvg-1 RNA andthe 88mer ofhvg-2and hvg-3were
enzymatically synthesized by in vitro transcription, using T7
RNA polymerase on a synthetic DNA template. The templates
50-CTTTAGCTCAGCGGTTACTTCGACAGTTCTTTAAT-
TGAAACAAGCAACCTGTCTGGGTTGTTCGAGACCCG-
CGGGC-30 (hvg-1), 50-CTTTAGCTCAGCGGTTACTTC-
GAGTACATTGTAACCACCTCTCTGGGTGGTTCGAGA-
CCCGCGGGTGCTTTCCAGCTCTTTT-30 (hvg-2) and 50-
CTTTAGCTCAGCGGTTACTTCGCGTGTCATCAAAC-
CACCTCTCTGGGTTGTTCGAGACCCGCGGGCGCTCT-
CCAGCCCTCTT-30 (hvg-3) were synthesized. To generate
the double-stranded DNA and to add the T7 promoter to the
template, we synthesized one common forward primer and
three individual reverse primers [forward primer, 50-AGTAA-
TACGACTCACTATAGGGCTGGCTTTAGCTCAGCGGTT-
ACTTC G-30; and reverse primers, 50-AAAAGGACTGGA-
GAGCGCCCGCGGGTCTCGAACAACCCA-30 (hvg-1), 50-
AAAAGAGCTGGAAAGCACCCGCGGGT-30 (hvg-2) and
50-AAGAGGGCTGGAGAGCGCCCGC-30 (hvg-3)]. Using
the template DNA and the primers, we prepared the
double-stranded DNA template, which now contained a T7
promoter (in italics), by using a commercial PCR kit (Ex Taq
kit, Takara, Japan). The reaction mixture was cycled at 94 C
f o r1m i n1 0s e c ,5 5  Cf o r5 0s ,a n d6 8  C for 1 min 10 sec for
10 cycles. The PCR product was precipitated and used for
RNA preparation by in vitro T7 transcription. Transcription
was performed at 37 C for 3 h, by using AmpliScribe tran-
scription kit. Later, the products were treated with 2 U of
DNase I (RNase free) for 10 min at 37 C, to remove the
template DNA, and were mixed with an equal volume of
2· urea buffer (7 M urea, 50 mM EDTA, 90 mM Tris-
borate containing 0.05% bromophenol blue). The reaction
mixtures were denatured at 90 C for 2 min and fractionated
on a 10% polyacrylamide gel containing 7 M urea. The RNA
band was excised, and the RNA was eluted from the gel. The
RNAs were concentrated by vacuum ﬁltration, redissolved in
water and then quantitated by the absorbance at 260 nm.
Circular Dichroism (CD) analysis
Circular dichroism titrations were carried out at 25 Co na
J-720 spectropolarimeter (JASCO). The starting volume in the
1 cm path length cell was 3 ml, with 1 mM of RNA in a buffer
containing 20 mM MgCl2, 50 mM Tris–HCl (pH 8.3 at 25 C)
and 100 mM KCl. Control experiments included spectra
obtained in the presence of only drug or buffer. Spectra
were collected immediately after the addition of a stock
solution of mitoxantrone or doxorubicin to a ﬁnal concentra-
tion of 4 or 16 mM. Each concentration was titrated ﬁve times.
In-line probing of RNA
RNAswere synthesizedenzymatically from the corresponding
PCR DNA templates by in vitro transcription using T7 poly-
merase and were labeled at the 30 end (15). The labeled RNA
was incubated for 40 h at 25 C, in a buffer containing 20 mM
MgCl2, 50 mM Tris–HCl (pH 8.3 at 25 C) and 100 mM KCl,
in the absence or in the presence of drug concentrations rang-
ing from 2 to 8 mM. After each incubation, the spontaneously
cleaved products were resolved by 12% denaturing (8 M urea)
PAGE followed by autoradiography.
Post-transcriptional inhibition assay
We usedthe rapidtranslation system (RTS)of the pIVEX GST
fusion vector (Roche), which constitutively expresses the
reporter gene from a T7 promoter, for complete in vitro trans-
lation analyses. In order to reduce the length of the intervening
sequences between the T7 promoter and the start codon of
glutathione S-transferase (GST) protein to <100 nt, upon
inserting the hvg-RNAs, we deleted some regions between
the T7 promoter, the ribosome binding site and the start
codon from the vector, using the NaeI and BsmI restriction
sites. These regions were regenerated by the insertion of the
truncatedregions containing20–77ntofhvg-1and20–67ntof
hvg-2 and hvg-3. Using the corresponding forward and reverse
primers [forward primers, 50-GGTGATGCCGGCAAATTA-
ATACGACTCACTATAGGGTTACTTCGACAGTTCTTT-30
(hvg-1), 50-GGTGATGCCGGCAAATTAATACGACTCA-
CTATAGGGTTACTTCGAGTACATTGT-30 (hvg-2), 50-GG-
TGATGCCGGCAAATTAATACGACTCACTATAGGGTTAC-
TTCGCGTGTCATCA-30 (hvg-3) and reverse primers, 50-
GGGGAATGCTACATGGTATATctccttCTTAAAGTTAA-
ACAAGGGTCTCGAACAACCCAG-30 (hvg-1), 50-GGG-
GAATGCTACATGGTATATctccttCTTAAAGTTAAACA-
AGGGTGTCGAACCAGCCAG-30 (hvg-2) and 50-GGGGA-
ATGCTACATGGTATATctccttCTTAAAGTTAAACAAG-
GGTCTCGTTCTTCCCAG-30 (hvg-3)], we ampliﬁed the
appropriate vRNA sequences from the vRNA templates
used in the above studies. The resulting fragments were
inserted into the pIVEX-GST expression vector using the
NaeI and BsmI restriction sites (underlined). The fragments
included the T7 promoter (in italics), the ribosome binding
site (in lowercase letters) and the initiation codon (in bold).
Using the similar sequences, hvg-1, with mutations at nt 53,
54, 58 and 59, was also engineered into the same vector
system. The modiﬁed pIVEX-GST fusion vectors inserted
with the vRNAs were translated in vitro i nt h ep r e s e n c eo f
mitroxantrone, using the rapid translation system RTS 100
Escherichia coli HY (Roche), according to the manufac-
turer’s instructions. The [
35S]methionine-labeled proteins
were generated by a coupled transcription/translation system
and were used as probes to detect vRNA interactions with
mitoxantrone. The gene products were identiﬁed by autora-
diography following SDS–PAGE (Daiichi Pure Chemicals
Co., Ltd) and were quantitated (radioactivity) using a
Bio image analyzer, BAS 2500 (Fuji Film), after drying
the gels.
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MDR, a major cause of cancer treatment failure, is a phenom-
enon whereby cancer cells develop broad resistance to a wide
variety of chemotherapeutic drugs (16). Cells utilize several
mechanisms to prevent cytotoxic drugs from reaching their
target sites, including protein modiﬁcation of the drugs,
up-regulation of plasma membrane pumps and reduction of
the nuclear-cytoplasmic ratio by increasing drug export from
the nucleus. Multidrug resistant cell lines have been shown to
utilize these routes to gain resistance to various drugs. The
unexpected role of vaults in MDR is supported by the follow-
ing evidence: (i) vaults and their components are over-
expressedincellstreatedwithcytotoxiccompounds;(ii)vaults
are involved in nucleo-cytoplasmic transport; (iii) compounds
that interact with the vaults reside within the vaults. Despite
these ﬁndings, neither vaults nor their components were
directly shown to bind the drugs. In order to test this possi-
bility, we have analyzed the ability of various chemotherapeu-
tic compounds to interact with vRNAs, as described below.
Analysis of vRNA binding to the mitoxantrone by CD
In the present study, we tested two chemotherapeutic
compounds, mitoxantrone and doxorubicin, for their ability
to interact with the non-coding RNAs associated with the vault
complex. As a preliminary assessment, we conducted CD
analyses and studied the binding region by an in-line probing
assay. The CD spectra were collected immediately after the
addition of mitoxantrone, to ﬁnal concentrations of 4 and
16 mM, to a buffered solution of the RNA. The ﬁnal spectrum
was obtained after subtracting the spectra of the buffer blank
and the drug. When mitoxantrone was added, a decrease in
the intensity at  265 nm and an increase in the intensity at
 255 nm were observed in the hvg-1 (Figure 1a) and hvg-2
spectra (Figure 1b), but not in the hvg-3 spectra (Figure 1c). In
order to see the distinct spectral changes, we have also plotted
the mitoxantrone dose-dependent response at 267 nm
(Figure 1d). This indicates that hvg-1 and hvg-2, but not
hvg-3, interact with mitoxantrone, which presumably results
in structural changes at the drug binding site. On the other
hand, when doxorubicin was added, no spectral change was
observed for either hvg-1, hvg-2 or hvg-3 (Figure 2a–c). These
studies suggest that hvg-1 and hvg-2 have the ability to bind
speciﬁcally to mitoxantrone, whereas hvg-3 has either weak or
no binding ability (Figure 1d), in spite of the high similarity
between these RNAs. Since the secondary structures of the
vRNA differ in the regions other than the 50 and 30 ends, these
unique regions probably account for the differences in
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Figure1.(a)CDspectraofhvg-1withdifferentconcentrationsofmitoxantrone(drugconcentrationsinparentheses).Circulardichroismtitrationswerecarriedoutat
25 C on a J-720 spectropolarimeter (JASCO). The starting volume in the 1 cm path length cell was 3 ml, with 1 mM of RNA in a buffer containing 20 mM MgCl2,
50 mM Tris–HCl (pH 8.3 at 25 C) and 100 mM KCl. RNAs were synthesized from the corresponding PCR DNA templates by in vitro transcription using T7 RNA
polymerase. (b) CD spectra of hvg-2 with different concentrations of mitoxantrone. (c) CD spectra of hvg-3 with different concentrations of mitoxantrone.
(d) Relative CD spectral changes of vRNAs at 267 nm with different concentrations of mitoxantrone.
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doxorubicin does not interact with any of the hvg-RNAs.
Identification of a mitoxantrone binding region
in vRNAs by an in-line probing assay
Next, we wished to determine the mitoxantrone binding region
in these vRNAs, using an in-line probing assay, which relies
on the structure-dependent spontaneous cleavage of RNA
(13,17). This sensitive assay has been successfully used to
map the binding sites of small molecules in RNA (13). In
this assay, the inter-nucleotide linkages between the bases
involved in secondary structure interactions are less sensitive
to spontaneous hydrolysis than those in the unstructured
regions. A signiﬁcant alteration in the RNA structure upon
ligand binding is reﬂected by a change in the cleavage pattern
(18). Using this assay, we monitored the spontaneous cleavage
of vRNA in the presence or in the absence of the correspond-
ing ligands (mitoxantrone and doxorubicin). Among the three
vRNAs tested with mitoxantrone and doxorubicin, we
detected an enhancement in the spontaneous cleavage of
hvg-1 upon the addition of mitoxantrone (2–4 mM)
(Figure 3a). We observed that the hvg-1 RNA region spanning
nt 49–59 was particularly sensitive to increasing concentra-
tions of mitoxantrone (close view, Figure 3b). Using the
ImageJ program (free software from http://rsb.info.nih.gov),
we carried out a quantitative analysis of the hydrolyzed prod-
ucts obtained in the absence and in the presence of mitox-
antrone, in the above region. The band (G58 nt) marked with
an arrowhead displayed enhanced cleavage as it attained a
saturationpoint at2–4mMof mitoxantrone anddeclinedthere-
after. Similarly, the band (A53 nt) marked with an arrow
intensiﬁed with increasing concentrations of mitoxantrone,
representing about a 3-fold enhancement of cleavage in the
presence of 4 mM of mitoxantrone, as compared with the drug-
free proﬁle (Figure 3c). The cleavage positions at G58 and
A53 were not increased signiﬁcantly at concentrations higher
than 4 mM mitoxantrone, suggesting that the drug binds to
hvg-1 with an equilibrium dissociation constant (Kd) in the
sub-micromolar range. These positions are indicated on the
predicted secondary structure of hvg-1 RNA (Figure 3d).
Similarly, a mitoxantrone-mediated modulation was also
observed in hvg-2, with an increased or decreased level of
cleavedproductnearthebindingregionofnt38–51(Figure4a,
close view Figure 4b). In particular, the position highlighted
with an arrow-head (U51 nt) displayed enhanced cleavage
upon the addition of increasing concentrations of mitox-
antrone, representing more than a 3-fold increase as compared
with the control (Figure 4c). The bands (U39, C43 and C48)
marked with arrows also underwent speciﬁc modulation.
These residues are highlighted on the predicted secondary
structure of hvg-2 RNA (Figure 4d). In contrast, the hvg-3
RNA did not show any signiﬁcant difference in the cleavage
pattern from the ligand-free control (Figure 5a–d). The gel
patterns obtained for doxorubicin with hvg-1, hvg-2 and
hvg-3 did not exhibit any remarkable cleavage pattern, as
compared with the control (data not shown). Taken together,
the CD and in-line attack analyses clearly suggest that the
hvg-1 and hvg-2 RNAs speciﬁcally bind to mitoxantrone,
while the hvg-3 RNA does not, and further imply that the
ability to recognize various compounds is based on differences
in their 3D structures, which might have originated from point
mutations among these RNAs. In addition, it appears that two
of the vRNAs (hvg-1 and hvg-2) have the ability to interact
Figure 2. CD spectra of (a) hvg-1, (b) hvg-2 and (c) hvg-3 with different concentrations of doxorubicin.
Nucleic Acids Research, 2005, Vol. 33, No. 15 4877with mitoxantrone, despite the differences in their primary
sequences near the binding region. To evaluate their
interactions in a cellular context, we have carried out a
post-transcriptional inhibition assay.
Post-transcriptional inhibition assay to analyze
vRNA-mitoxantrone interactions
The ability of RNA to interact with small molecules, such as
antibiotics and metabolites, has been well documented in the
Figure3.(a)Arepresentativeautoradiogramshowinganin-lineprobingassayofinteractionsbetweenhvg-1andmitoxantrone.OH-alkalidigestion:T1(specificfor
G bases). RNAs were prepared by PCR from DNA templates and were labeled at the 30 end. The labeledRNA was incubated for 40 h at 25 C in a buffer containing
20mMMgCl2,50mMTris–HCl(pH8.3at25 C)and100mMKCl,withdrugconcentrationsrangingfrom2to8mM.Aftereachincubation,spontaneouslycleaved
products were resolved by 12% denaturing (8 M urea) PAGE followed by autoradiography. (b) Enlarged view: arrows and arrow heads indicate sites of enhanced
cleavage. (c) Quantitative analysis of cleaved products. (d) Secondary structure of RNA (RNA structure 3.71). The mitoxantrone binding region is indicated by
circles, and the specific residues are indicated as in (b).
Figure4.(a)Arepresentativeautoradiogramshowinganin-lineprobingassayofinteractionsbetweenhvg-2andmitoxantrone.(b)Enlargedview:arrowsandarrow
heads indicate sites of enhanced cleavage. (c) Quantitative analysis of cleaved products. (d) Secondary structure of RNA (RNA structure 3.71). The mitoxantrone
binding region is indicated by circles, and the specific residues are indicated as in (b).
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shownthatappendinganRNAmotif,which recognizesasmall
molecule, into the 50 untranslated region of messenger RNA
allowed its translation to be repressed by ligand addition
in vitro as well as in vivo. The inhibition of the translation
product by these small molecules in this assay was attributed
to their ability to interfere with ribosome binding. Using this
assay, several small ligands that bind to RNAs have been
evaluated and explored for controlling gene expression in
living cells (17,20–22). In order to evaluate the observed inter-
actions between vRNAs and mitxantrone in terms of transcrip-
tion and translation, we employed a post-transcriptional
inhibition assay. To evaluate its suitability for our study,
we ﬁrst tested the general ability of the inhibition on the
coupled-transcription and translation, using RTS 100 E.coli
HY in vitro cell-free system, with increasing amounts of
mitoxantrone (2–8 mM), and found that this compound has
no inﬂuence on the efﬁciency of yielding the correct transla-
tion product (Figure 6a). In addition, the intervening
sequences within the template between the T7 promoter and
the start codon (AUG) region need to be restricted between
20 and 100 nt, for efﬁcient synthesis of the translation product
in a coupled-transcription and translation system (23). Hence,
this assay is more suitable for shorter RNA motifs that interact
with cognate ligands. To adapt this assay, we truncated the
50 and 30 ends from the full-length vRNAs, based on the in-line
probing assay, and appended these sequences immediately
downstream from the T7 promoter (Figure 6b). The minimal
vRNAs thus generated were mini-hvg-1 RNA (59mer,
sequences between 20 and 77 nt), mini-hvg-2 RNA (49mer,
20–67 nt) and mini-hvg-3 RNA (49mer, 20–67 nt). Before
appending these sequences, the intervening sequence of the
vector (pIVEX-GST) between the T7 promoter and start
codon, including the ribosome binding site, was removed
by digestions with restriction enzymes (see Materials and
Methods for details on the vector construction), and then
the ribosome binding site was generated together with the
minimal vRNAs sequences by cloning. The resulting vectors
were pIVEX-GSThvg-1, pIVEX-GSThvg-2 and pIVEX-
GSThvg-3. To evaluate the importance of the sequence
near the mitoxantrone binding site, based on the in-line prob-
ing assay results, we alsopreparedthe hvg-1 RNA mutant with
53A, 54A and 58G, 59U substituted with 53U, 54U and 58C,
59A, respectively (pIVEX-GSTmut-hvg-1). The resulting
intervening sequences, upon transcription, between the T7
promoter and the start codon (AUG) are 87, 77, 77 and
87 nt for the vectors pIVEX-GSThvg-1, pIVEX-GSThvg-2,
pIVEX-GSThvg-3 and pIVEX-GSTmut-hvg-1, respectively.
These vectors yielded 30000 Da translated products, although
pIVEX-GSThvg-1 and pIVEX-GSTmut-hvg-1 produced
lower amounts of the translation products, as compared
with the other two vectors. This could be due to the extra
10 nt between the T7 promoter and the start codon.
Using these vectors, we carried out coupled-transcription
and translation reactions in the absence and in the presence of
various concentrations of mitoxantrone (2–8 mM), and ana-
lyzed the amounts of translation products synthesized. The
hvg-1 and hvg-2 containing transcripts yielded decreasing
amounts of translational products with increasing concentra-
tions of mitoxantrone (Figure 6c). However, the hvg-3 tran-
script was translated efﬁciently, even in the presence of 8 mM
mitoxantrone. The reduction in the amount of translational
product is attributable to an interference with ribosome bind-
inguponmitoxantronebinding,speciﬁcallywith thehvg-1and
hvg-2 motifs, as observed for antibiotics and metabolites in
previous studies (20,24). On the other hand, when the residues
of hvg-1 that were involved in the mitoxantrone binding were
substituted(53A,54Aand58G,59Uto53U,54Uand58C,59A),
Figure 5. (a)Arepresentativeautoradiogramshowingtheresultsofanin-lineprobingassayofhvg-3andmitoxantrone.(b)Enlargedview.(c)Quantitativeanalysis
of cleaved products. (d) Secondary structure of RNA (RNA structure 3.71).
Nucleic Acids Research, 2005, Vol. 33, No. 15 4879the mitoxantrone-dependent inhibition was not observed
(Figure 6c). Quantiﬁcation of these results clearly suggested
that the hvg-1 and hvg-2 RNA motifs have the ability to
recognize and bind mitoxantrone speciﬁcally (Figure 6d).
Considering the current study, including the CD analysis,
the in-line probing and the translational inhibition assay, it is
clear that the hvg-1 and hvg-2 RNAs bind to mitoxantrone. A
common asymmetric loop region is found when compared
Figure 6. Post-translation inhibition assay. (a) Synthesis of translated product (30000 daltons) using pIVEX-GST in the presence of mitoxantrone (2–8 mM) in an
E.coli in vitro system. (b) A model system to analyze the interactions betweenmitoxantroneand vRNAs.(c) Synthesis efficiency of translatedproducts ofdifferent
vRNAsintheabsenceandinthepresenceofmitoxantrone(2–8mM).Thearrowindicatesthepositionofthetranslatedproduct.(d)Quantitativedataoftranslational
products synthesized by the four different vRNAs (values are averages of three experiments).
4880 Nucleic Acids Research, 2005, Vol. 33, No. 15between these two RNAs based on predicted secondary struc-
tures and this loop is absent in hvg-3 RNA.However, we could
not observe apparent cleavage sites (under in-line probing
studies)in thisloop region inthe presence of the mitoxantrone.
Similar tertiary structure to recognize mitoxantrone by these
two RNAs (hvg-1 and hvg-2) might be another distinct pos-
sibility for binding and extrusion of the drug. The physiolo-
gical relevance of the interaction of vRNAs with mitoxantrone
has not been deﬁned yet. However, it is tempting to speculate
about their importance, based on previous observations of
the overexpression of vault complexes (containing three
hvg-RNAs and three proteins) associated with resistance to
chemotherapeutic compounds (25). Despite these observa-
tions, neither the vRNAs nor the associated proteins have
been implicated or shown todirectlyinteractwith chemothera-
peutic compounds. On the other hand, vault-associated
proteins have been implicated in a cytoskeletal-mediated
transport pathway between the nucleus and cytoplasm (6).
The studies presented above clearly indicated, for the ﬁrst
time, that the vault-associated non-coding RNAs, such as
the hvg-1 and hvg-2 RNAs, have the ability to bind and
sequester mitoxantrone. The vault-associated proteins may
be involved in export, to prevent the drug from reaching
the site of action. Indeed, more studies are required to inves-
tigate the binding of vRNAs to other chemotherapeutic
compounds. In addition, the generation of vRNA knockout
cells may help to reveal the function of vRNAs and their
signiﬁcance in the complex.
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